絞り込み

17379

広告

マツタケ、絶滅危惧種に指定 (デイリースポーツ)

国際自然保護連合(IUCN)は9日、世界の絶滅危惧種をまとめたレッドリストの最新版を公表した。日本に関連する動植物では、新たに高級キノコのマツタケや沖縄県に生息...

  1. 第1回薬剤師の養成及び資質向上等に関する...
  2. 加藤厚生労働大臣 閣議後記者会見のお知ら...
  3. マツタケ、絶滅危惧種に 栽培困難、山の環...
  4. 囲碁 井山三冠 本因坊戦9連覇 七大タイ...

ニュース一覧

Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban.

著者 Pelliccia F , Rosanio S , Marazzi G , Poggi S , Tanzilli A , Greco C , Gaudio C , Rosano G
Int J Cardiol.2016 Oct 1 ; 225():77-81.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (55view , 0users)

Full Text Sources

Medical

Research Materials

The high risk of both stroke and major bleeding in atrial fibrillation (AF) patients with chronic kidney disease (CKD) defines an important population for whom the assessment of the balance between the risk of ischemic stroke and of bleeding is essential. The use of novel oral anticoagulants (NOACs) may be a viable option in this population due to their greater net clinical benefit than warfarin, as demonstrated by the results of the clinical phase III trials. NOACs have been found to have a greater net clinical benefit than warfarin in patients at high risk of either stroke (CHADS2≥1 or CHA2DS2-VASc score≥2) or bleeding (HAS-BLED≥3). Noteworthy, it has been found also a positive net clinical benefit with apixaban and dabigatran 110mg BID in patients with CHADS2 score=0 and HAS-BLED score≥3. At CHA2DS2-VASc score=1, apixaban and both doses of dabigatran were superior to warfarin in terms of the net clinical benefit. Available scientific evidence might help in clinical decision-making regarding the use of NOACs in patients with CKD who are at high risk for both stroke and bleeding. Overall, current findings provide a rationale for the choice of apixaban or rivaroxaban over dabigatran in patients with AF and stage III CKD. Out of the NOACs, only apixaban has been recently approved for the use in patients with end-stage renal dysfunction on hemodialysis (the recommended dose of 5mg twice daily should be halved in patients with body weight of ≤60kg and or age≥80years).
PMID: 27716554 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード